Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023 04:00 ET
|
Alvotech
REYKJAVIK, Iceland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023 04:00 ET
|
Alvotech
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech...
Alvotech birtir uppgjör fyrir fyrstu níu mánuði ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðungi
November 28, 2023 16:15 ET
|
Alvotech
Heildarsölutekjur fyrstu níu mánuði ársins jukust í 29,8 milljónir dollara, samanborið við 11,1 milljón dollara á sama tímabili í fyrraMarkaðsleyfi var veitt fyrir AVT04 í Kanada og Japan, fyrstu...
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
November 28, 2023 16:15 ET
|
Alvotech
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
November 28, 2023 16:15 ET
|
Alvotech
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
November 21, 2023 08:00 ET
|
Alvotech
REYKJAVIK, ICELAND, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
November 14, 2023 07:00 ET
|
Alvotech
PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) --...
Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara
November 14, 2023 07:00 ET
|
Alvotech
Jamteki (AVT04) er önnur líftæknilyfjahliðstæðan sem samstarfsfélögin setja á markað í Kanada Alvotech (NASDAQ: ALVO) og JAMP Pharma Group („JAMP Pharma“) tilkynntu í dag Heilbrigðisstofnun Kanada,...
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
November 14, 2023 07:00 ET
|
Alvotech
JamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development...
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
November 10, 2023 09:30 ET
|
Alvotech
CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo...